阿替妥珠单药治疗非小细胞肺癌患者：茨城团体的观察性研究（ATTENTION-IBARAKI）。
Atezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI).
发表日期：2023
作者：
Shinichiro Okauchi, Gen Ohara, Toshihiro Shiozawa, Hiroko Watanabe, Takeshi Numata, Ryota Nakamura, Tomohiro Tamura, Norihiro Kikuchi, Kunihiko Miyazaki, Shigen Hayashi, Hirofumi Sakurai, Takaaki Yamashita, Koichi Kurishima, Masaharu Inagaki, Takeo Endo, Hiroichi Ishikawa, Takayuki Kaburagi, Hiroaki Satoh, Toru Sakamoto, Nobuyuki Hizawa
来源：
Cellular & Molecular Immunology
摘要：
阿特珠单抗是一种靶向癌细胞和抗原呈递细胞表达的 programmed death-ligand 1（PD-L1）的单克隆抗体，目前常与化疗联合使用。我们进行了一项研究，旨在澄清阿特珠单抗单药治疗在临床实践中的当前响应状况，并阐明对长期响应和生存做贡献的因素。我们对11家医院从2018年4月至2023年3月期间接受阿特珠单抗单药治疗的晚期非小细胞肺癌（NSCLC）患者进行了回顾性研究。评估的147名患者的无进展生存期为3.0个月，总生存期为7.0个月。13名患者（8.8％）观察到任何级别的免疫相关不良事件，9名患者（6.1％）观察到3级或更高级别的不良事件，而1名患者（0.7％）出现了肺毒性相关的5级不良事件。与腺癌以外的NSCLC类型相关是无进展生存期的有利因素。而总生存期的有利因素为“Performance status 0-1”和“治疗线路至多3条”。其中有16名患者（10.9％）的无进展生存期超过1年。与其余131名患者相比，这16名患者中未发现特征性临床发现。阿特珠单抗单药治疗相关的NSCLC患者的疗效和免疫相关不良事件与先前临床试验结果相当。了解那些最有可能从阿特珠单抗单药治疗中获益的患者的特征是实施适当处方的关键一步。
2023年国际抗癌研究所（Dr. George J. Delinasios）版权所有。保留所有权利。
Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) expressed on cancer cells derived from various organs and antigen-presenting cells and is currently commonly used in combination with chemotherapy. We conducted a study to clarify the current status of response to atezolizumab monotherapy in clinical practice and clarify the factors that contribute to long-term response and survival.We conducted a retrospective review of patients with advanced non-small cell lung cancer (NSCLC) treated with atezolizumab monotherapy from April 2018 to March 2023 at 11 Hospitals.The 147 patients evaluated had a progression-free survival (PFS) of 3.0 months and an overall survival of 7.0 months. Immune-related adverse events of any grade were observed in 13 patients (8.8%), grade 3 or higher in nine patients (6.1%), and grade 5 with pulmonary toxicity in one patient (0.7%). Favorable factors related to PFS were 'types of NSCLC other than adenocarcinoma'. Favorable factors for overall survival were 'performance status 0-1' and 'treatment lines up to 3'. There were 16 patients (10.9%) with PFS >1 year. No characteristic clinical findings were found in these 16 patients compared to the remaining 131 patients.Efficacy and immune-related adverse events of NSCLC patients associated with atezolizumab monotherapy were comparable to those of previous clinical trial results. Knowledge of characteristics of patients who are most likely to benefit from atezolizumab monotherapy is a crucial step towards implementing appropriate prescribing.Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.